Frank M Biro1, Susan M Pinney2, Richard C Schwartz3, Bin Huang4, Ashley M Cattran5, Sandra Z Haslam6. 1. Division of Adolescent and Transition Medicine, Cincinnati Children's Hospital Medical Center, Cincinnati, Ohio; Department of Pediatrics, University of Cincinnati College of Medicine, Cincinnati, Ohio. Electronic address: frank.biro@cchmc.org. 2. Department of Environmental Health, University of Cincinnati College of Medicine, Cincinnati, Ohio. 3. Department of Microbiology and Molecular Genetics, Michigan State University, East Lansing, Michigan. 4. Department of Pediatrics, University of Cincinnati College of Medicine, Cincinnati, Ohio; Department of Biostatistics and Epidemiology, Cincinnati Children's Hospital Medical Center, Cincinnati, Ohio. 5. Department of Pediatrics, University of Cincinnati College of Medicine, Cincinnati, Ohio. 6. Department of Physiology, Michigan State University, East Lansing, Michigan.
Abstract
STUDY OBJECTIVE: Amphiregulin is a member of the epidermal growth factor family. In breast tissue, amphiregulin is a mediator of estrogen and progesterone signaling. The objectives were to examine the relationship of amphiregulin levels during peripuberty with estrogen levels. DESIGN, SETTING, PARTICIPANTS, INTERVENTIONS, AND MAIN OUTCOME MEASURES: The participants in this analysis were a subset from a longitudinal study of pubertal maturation, the Breast Cancer and the Environment Research Program. They were recruited between ages 3 and 7 years. Blood specimens were selected for hormone analysis between 24 months before and 6 months after breast development. Serum amphiregulin levels were analyzed using enzyme-linked immunosorbent assay. RESULTS: Amphiregulin levels were measured in 188 girls; 8.5% had a maternal history of breast cancer, and 30.9% of samples were below the limit of detection. Amphiregulin levels were greatest at 18 months before the onset of breast development (P < .006), and the rise in estrone levels between -24 and -18 months was correlated with the increase in amphiregulin levels in the same time period (P = .0002). After adjustment for time relative to breast development, amphiregulin levels were associated with maternal breast cancer (P = .024). Tracking of amphiregulin levels was highly significant (P < .0001) within a given individual. CONCLUSION: Amphiregulin levels peaked at 18 months before the onset of breast development, were temporally related to the rise in serum estrone, and were significantly associated with maternal history of breast cancer. Elevated amphiregulin levels at puberty might be a predictor of increased breast cancer risk.
STUDY OBJECTIVE:Amphiregulin is a member of the epidermal growth factor family. In breast tissue, amphiregulin is a mediator of estrogen and progesterone signaling. The objectives were to examine the relationship of amphiregulin levels during peripuberty with estrogen levels. DESIGN, SETTING, PARTICIPANTS, INTERVENTIONS, AND MAIN OUTCOME MEASURES: The participants in this analysis were a subset from a longitudinal study of pubertal maturation, the Breast Cancer and the Environment Research Program. They were recruited between ages 3 and 7 years. Blood specimens were selected for hormone analysis between 24 months before and 6 months after breast development. Serum amphiregulin levels were analyzed using enzyme-linked immunosorbent assay. RESULTS:Amphiregulin levels were measured in 188 girls; 8.5% had a maternal history of breast cancer, and 30.9% of samples were below the limit of detection. Amphiregulin levels were greatest at 18 months before the onset of breast development (P < .006), and the rise in estrone levels between -24 and -18 months was correlated with the increase in amphiregulin levels in the same time period (P = .0002). After adjustment for time relative to breast development, amphiregulin levels were associated with maternal breast cancer (P = .024). Tracking of amphiregulin levels was highly significant (P < .0001) within a given individual. CONCLUSION:Amphiregulin levels peaked at 18 months before the onset of breast development, were temporally related to the rise in serum estrone, and were significantly associated with maternal history of breast cancer. Elevated amphiregulin levels at puberty might be a predictor of increased breast cancer risk.
Authors: Frank M Biro; Susan M Pinney; Bin Huang; Erin R Baker; Donald Walt Chandler; Lorah D Dorn Journal: J Clin Endocrinol Metab Date: 2014-07-16 Impact factor: 5.958
Authors: N Normanno; C Qi; W Gullick; G Persico; Y Yarden; D Wen; G Plowman; N Kenney; G Johnson; N Kim; R Brandt; I Martinezlacaci; R Dickson; D Salomon Journal: Int J Oncol Date: 1993-06 Impact factor: 5.650
Authors: Esther A Peterson; Edmund C Jenkins; Kristopher A Lofgren; Natasha Chandiramani; Hui Liu; Evelyn Aranda; Maryia Barnett; Paraic A Kenny Journal: Cancer Res Date: 2015-11-02 Impact factor: 12.701
Authors: Mark D Aupperlee; Yong Zhao; Ying Siow Tan; Jeffrey R Leipprandt; Jessica Bennett; Sandra Z Haslam; Richard C Schwartz Journal: Endocrinology Date: 2014-04-02 Impact factor: 4.736
Authors: Y Lemos-González; F J Rodríguez-Berrocal; O J Cordero; C Gómez; M Páez de la Cadena Journal: Br J Cancer Date: 2007-04-24 Impact factor: 7.640
Authors: Mary Beth Terry; Karin B Michels; Julia Green Brody; Celia Byrne; Shiuan Chen; D Joseph Jerry; Kristen M C Malecki; Mary Beth Martin; Rachel L Miller; Susan L Neuhausen; Kami Silk; Amy Trentham-Dietz Journal: Breast Cancer Res Date: 2019-08-20 Impact factor: 8.408
Authors: Melissa C Friesen; Hyoyoung Choo-Wosoba; Philippe Sarazin; Jooyeon Hwang; Pamela Dopart; Daniel E Russ; Nicole C Deziel; Jérôme Lavoué; Paul S Albert; Bin Zhu Journal: J Expo Sci Environ Epidemiol Date: 2021-05-18 Impact factor: 5.563